Stifel cuts Compass Therapeutics stock price target on FDA uncertainty By Investing.com

Stifel cut Compass Therapeutics’ price target to $6 from $12 while keeping a Buy rating, citing uncertainty over FDA interpretation of COMPANION-002 secondary endpoints for tovecimig. The trial showed a 0.44 progression-free survival hazard ratio but an overall survival hazard ratio of 1.05 in the intent-to-treat group, with a 54% crossover rate complicating the readout. The stock trades at $1.74 versus a $6.88 52-week high, and the regulatory path may hinge on whether the FDA allows flexibility on overall survival for approval.

Analysis

The market is still treating CMPX like a binary regulatory event, but the more important setup is asymmetry around timing. A positive read from FDA on crossover-adjusted survival could re-rate the stock sharply because the current valuation implies near-zero probability of eventual monetization; however, any ambiguity pushes commercialization well into 2027+ and forces another financing cycle. That combination makes the equity less a single-asset story than a diluted call option on both regulatory interpretation and pipeline optionality.

Second-order, the crossover issue is a double-edged sword: it weakens the clean statistical package for approval, but it also signals that clinicians were willing to switch, which can matter for label credibility and eventual uptake if the agency is flexible. If the FDA leans conservative, the likely winner is not a direct competitor in BTC so much as other oncology names with cleaner registrational packages and earlier readouts, because capital will rotate toward lower-regulatory-risk assets. On the loser side, CMPX faces a higher cost of capital and weaker negotiating leverage with partners if the approval path stretches out.

The near-term catalyst path is crowded into the next 1-3 months, but the real tail risk sits 6-12 months out: either a delay to an accelerated-approval discussion or a request for additional data that forces dilution before value realization. The contrarian view is that the market may be over-discounting the survival miss because it is not a pure failure; if the agency accepts the crossover-adjusted narrative, the stock could double from depressed levels before fundamentals catch up. That said, this remains a high-volatility setup where the base case is not a fast approval, but a prolonged regulatory overhang with multiple drawdowns around headline risk.

Key Decisions for Investors

• Buy CMPX only as a tight-risk event trade into regulatory clarification; use defined-risk call spreads or a small equity starter position with a 30-60 day horizon. Upside can be multiple turns if FDA signals flexibility, but size should reflect dilution and binary headline risk.
• Sell CMPX rallies into strength if the stock rebounds on trial-interpretation speculation; the path to approval appears long enough that upside is likely to be interrupted by financing and guidance risk over the next 6-12 months.
• Pair trade: long a basket of oncology names with cleaner registrational visibility against short CMPX for the next 2-4 months. The thesis is relative de-risking, not sector weakness; capital should migrate toward assets with less regulatory ambiguity.
• If already long CMPX, hedge with short-dated puts into known FDA communication windows. The premium is justified because a conservative agency read could compress the stock another 30-50% before any new catalyst emerges.
• Avoid initiating large unhedged positions ahead of binary news; only add after either a positive FDA interpretive signal or a financing event that resets the capital structure and removes near-term solvency overhang.